Metabolic effects of lithium
|
|
- Prudence Johnston
- 6 years ago
- Views:
Transcription
1 Metabolic effects of lithium Leonardo Tondo, MD, MSc Centro Lucio Bini, Cagliari & Roma McLean Hospital-Harvard Medical School
2 Collaborators Ross J. Baldessarini, MD Mirko Manchia, MD Marco Pinna, PsyD
3 Research Funding and Disclosure Mood Disorder Lucio Bini Center and Aretæus Onlus, Roma Anderson Foundation, Boston, USA Stanley Medical Research Institute, USA Advisor for Angelini
4 Meta-analysis: Efficacy studies lithium in MDI
5 Adverse Effects of Lithium (general) Development Ebstein's (tricuspid & septal defects) ca. 1/2500 No excess spina bifida (vs. VPA, CBZ) General Weight-gain* Worsening of acne, variable alopecia Mild WBC increase (not leukemia precursor) Drug interactions Thiazides, NSAIDs increase [Li + ] levels [*] Strongly associated with discontinuation.
6 Adverse Effects of Lithium (organ specific) Nervous system Lethargy, weakness, mild confusion, tremor* Overdose delirium: potential severe brain damage Myasthenia may worsen Kidney Low GFR Early polyuria and thirst Later diabetes insipidus Thyroid Occasional diffuse goiter (not precursor of cancer) Mild hypothyroidism, early TSH elevation [*] Strongly associated with discontinuation.
7 Lithium Adverse Affects vs. Adherence Rank Frequency Bothersome Contribution to stopping 1 Thirst Weight Cognition loss 2 Polyuria Cognition loss Weight gain 3 Weight gain Polyuria Tremors 4 Fatigue Nausea Slowness 5 Dry mouth Fatigue Incoordination 6 Sleepiness Impaired balance 7 Diarrhea Dizziness 8 Concentration Diarrhea 9 Tremor 10 Memory impaired 43% of 51 patients showed some noncompliance Cognition: subjective memory, concentration, confusion & slowness (depression?) Da: Gitlin et al: J Clin Psychiatry 1989
8 Cognitive Impairments Effect-Size versus Healthy Controls Patients Relatives Patients Relatives Bipolar Disorder Trails-B CPT Digit-Symbol Trails-A WCST IQ [ES = Cohen s d-statistic] Schizophrenia [Adapted from: Bora et al. J Affect Disord. 2009;113:1 20; Dickinson et al. Arch Gen Psychiatry 2007;64: ]
9 Lithium and Pregnancy Risks Outcome OR [95%CI] p-value Miscarriage Lithium exposure Bipolar disorder Cardiovascular anomaly* Lithium exposure Bipolar disorder 1.94 [ ] 0.96 [ ] 4.75 [ ] 5.43 [ ] Subjects (n): 152 lithium-exposed; 842 controls. [*] Risk of Ebstein s anomaly with lithium: 0.66% (1/152), based on a single case From Diav-Citrin et al. Am J Psychiatry 2014; 171:
10 Lithium Toxicity (meta-analysis) Studies Pooled Measure p-value Urine conc. Ability [ 230 to +87.1] mosm/kg < GFR [ 14.6 to +2.20] ml/min Renal failure 18/3369 cases (0.534%) TSH increase [ ] iu/ml < PTH increase [ ] pg/ml < Calcium increase [ ] mmol/l Weight-gain OR = [ ] Congenital defects No significant increase
11 From Shine et al.: Lancet, May 2015 (UK data).
12 From Shine et al.: Lancet, May 2015 (UK data).
13 Renal Failure With Lithium Age & Exposure Age: Ill 5 years Ill 10 years Age: 50 Ill 5 years Ill 10 years Condition Renal Failure (%) No Lithium With Lithium Adjusted HR [95% CI] Lithium 2.60 [ ] Diabetes 2.70 [ ] Data based on UK general practice database (N=6264 cases of BD). HR model is adjusted for age and sex; mean exposure ca. 7 years. Age >50 greatly increased risk. Renal impairment 3x higher with lithium (10%/3%). From Close H, et al. PLOS One 2014; 9:e90169
14
15 Adverse Outcomes: Mood-Altering Agents for BPD Outcome/ADR Li ACs APDs ADs Acute efficacy poor no LTG/mania no yes Prophylaxis uncertain no CBZ, VPA yes yes Sedation/Lethargy variable variable yes rare Neurological rare EPS cognitive variable EPS no Headache no yes no rare GI Distress early variable no SRIs Weight-gain yes yes CLZ, ONZ, QTP variable Hypertension no no no variable Diabetes II no no CLZ, ONZ, QTP no Hypothyroidism common no no no Renal effects predictable no no no SIADH/Hyponatremia rare oxcbz, CBZ variable SRIs Dermatologic yes LTG, CBZ rare no Hepatic no VPA, CBZ rare no Bone marrow no CBZ, VPA CBZ rare Drug-interactions NSAIDs, diuretics CBZ, VPA rare SRIs Teratogenic rare VPA>CBZ>LTG not proved not certain Li = Lithium; ACs = anticonvulsants; APDs = antipsychotic drugs; ADs = antidepressants.
16 Valproate-Induced Hyperammonemia Encephalopathy/delirium rare Risk independent of sex, age, or exposure-time CNS severity poorly associated with serum levels of [NH 3 ] or [VPA] Recovery usual when VPA discontinued L-Carnitine may help ( mg/kg/day) From Dealberto MJ: Int Clin Psychopharmacol 2007; 22: ; Wadzinski J et al: J Am Board Fam Med 2007; 20: ; LoVecchio F et al. Am J Emerg Med 2005; 23:
17 IGSLi Collaborative Study Multisite study Patients on lithium for at least 8 years Demographic and clinical variables: sex, BMI, somatic illnesses, onset and current age, diagnosis, type of first episode, suicide acts, SUD, sigarette smoking, alcohol consumption, use of ADs, ACs, or APs Lithium treatment: Dosage and plasma levels, and response to treatment (Alda scale) Lab tests: WBC, FBS, BUN, Creatinine, TSH, FT3, FT4
18 Subjects and Data Analysis Participating sites = 11 Patients = 220 Average of blood levels by year of treatment Comparisons between baseline and 5, 10, 15, 20, 25, 30, and 30 years of treatment
19 Institution Participating Centers and Subjects N La Sapienza University, Lucio Bini Mood Center, Rome, Italy 48 Lucio Bini Mood Disorder Center, Cagliari, Italy 36 Dalhousie University, Halifax, Canada 33 University of Cagliari, Italy 30 University of Barcelona, IDIBAPS, CIBERSAM, Spain 26 University of Palermo, Buenos Aires, Argentina 25 Viarnetto Hospital, Lugano, Switzerland 23 University of Dresden, Germany 22 University of Poznan, Poznan, Poland 20 University of Pisa, Italy 20 University of Frankfurt, Germany 6
20 Participants Martin Alda (Halifax) Ross J. Baldessarini (Boston) Alberto Bocchetta (Cagliari) Lorenza Bolzani (Lugano) Cindy Calkin (Halifax) Mirko Manchia (Cagliari) Giulio Perugi (Pisa) Marco Pinna (Cagliari) Daniela Reginaldi (Roma) Philipp Ritter (Dresden) Janusz Rybakowsky (Poznan) Gabriele Sani (Roma) Valerio Selle (Lugano) Leonardo Tondo (Cagliari) Eduard Vieta (Barcelona) Julia Volkert (Frankfurt) Giuseppe Quaranta (Pisa)
21 Preliminary Results Average duration of treatment = 11.9±8.40 years Mean Li dose = 854±303 mg/day Mean Li level = 0.67±0.18 meq/l
22 Secular Trend of Lithium Doses and Plasma Levels Year Li dose Li level Baseline (220) 814± ±0.22 Year 05 (220) 861± ±0.20 Year 10 (196) 846± ±0.18 Year 15 (121) 826± ±0.21 Year 20 (92) 812± ±0.18 Year 25 (54) 798± ±0.17 Year 30 (28) 797± ± (140) 773± ±0.17
23 Secular Trend of Parameters Associated with Years of Lithium Treatment Year Crea (mg/dl) WBC (10 9 xl) FBS (mg/dl) BUN (mg/dl) TSH (mlu/l) Baseline (220) 0.87± ± ± ± ±2.50 Year 05 (220) 0.87± ± ± ± ±1.96 Year 10 (196) 0.90± ± ± ± ±2.64 Year 15 (121) 0.89± ± ± ± ±1.97 Year 20 (92) 0.91± ± ± ± ±1.58 Year 25 (54) 0.96± ± ± ± ±8.66 Year 30 (28) 1.07± ± ± ± ± (140) 1.04± ± ± ± ±1.32
24 BUN and Creatinine vs. Years of Lithium Treatment Years BUN Creatinine F-score p-value F-score p-value <0.0001
25 100 Renal Function vs. Years of Lithium Treatment 90 [From Tondo et al., 2016; International study of 2669 measurements in 312 bipolar disorder subjectsl note : not all elevated assays were sustained] GFR (±95% CI) lower limit of normal GFR Lithium Exposure (years)
26 Renal Effects of Lithium Dosing Schedules Li Dose Urine Vol. Creatinine Creat. Clear. (meq/d) (ml/d) (µmol/l) (ml/min) Study Single Multi Single Multi Single Multi Single Multi Perry et al Plenge et al Schou et al Hetmar et al Muir et al Bowen et al Abraham et al O Donovan et al Kusalic et al Totals (n=9) ±SD ±5.9 ±4.5 ±426 ±880 ±14.0 ±11.7 ±18.2 ±20.3 Multi/Single Ratio paired-t [p] 2.92 [0.03] 1.13 [0.30] 2.31 [0.10] [0.59] Note that differences in urine volume, serum creatinine concentration and clearance do not differ significantly with lithium dosing schedule (one vs. 2 or 3 divided doses daily), but that the total daily dose averaged 15% greater with multiple daily dosing, potentially confounding other outcome measures. From Baldessarini R (unpublished, 2007).
27 Conclusions Lithium is still the most effective treatment in the recurrence prevention of mood disorders Adverse effects during long-term lithium treatment are not uncommon Cognitive effects, tremor, and weight gain most associated with nonadherence Kidney and thyroid effects are the most problematic Renal AEs start after about 10 years of treatment but renal failure is relatively rare Single (vs. multiple) dosing does not seem to be associated with reduction of renal AEs
POMH-UK QUALITY IMPROVEMENT PROGRAMME LITHIUM MONITORING. Thomas R. E. Barnes
POMH-UK QUALITY IMPROVEMENT PROGRAMME LITHIUM MONITORING Thomas R. E. Barnes LITHIUM Evidence-based guidelines support the use of lithium in the prophylaxis of bipolar disorder, protecting against both
More informationDr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/04/02)
DRUGS USED IN MOOD DISORDERS Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/04/02) LEARNING OUTCOMES By the end of the lecture, students will be able to describe the following with regard
More informationLITHIUM. Generic? Yes
LITHIUM THERAPEUTICS Brands Eskalith Eskalith CR Lithobid slow-release tablets Lithostat tablets Lithium carbonate tablets Lithium citrate syrup see index for additional brand names Generic? Yes Class
More informationMichael Kozart, MD, PhD
Michael Kozart, MD, PhD Review common abnormal lab results pertaining to Lithium, Depakote, Tegretol, Clozaril, Electrolytes/Calcium/Vitamin D, Renal, Liver and Thyroid Function, Diabetes, and Lipid Metabolism.
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationLITHIUM. Generic? Yes
LITHIUM THERAPEUTICS Brands Eskalith Eskalith CR Lithobid slow-release tablets Lithostat tablets Lithium carbonate tablets Lithium citrate syrup see index for additional brand names Generic? Yes Class
More informationApproach to Bipolar Disorder Family Medicine Forum November 14 17, 2018 Toronto, Ontario
Approach to Bipolar Disorder Family Medicine Forum November 14 17, 2018 Toronto, Ontario Jon Davine, MD, CCFP, FRCP(C) Associate Professor, McMaster University Faculty/Presenter Disclosure Faculty: Dr.
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More information7 Ways to Improve Lithium s Tolerability
7 Ways to Improve Lithium s Tolerability By Chris Aiken, MD Most of the adverse effects of lithium are manageable and a little knowledge goes a long way here. An unhealthy fear of lithium I have an unhealthy
More informationKidney, thyroid and other organ functions after 40 years or more of lithium therapy: a case series of five patients
643299TPP0010.1177/2045125316643299Therapeutic Advances in PsychopharmacologyA. Permoda-Osip et al. research-article2016 Therapeutic Advances in Psychopharmacology Review Kidney, thyroid and other organ
More informationSYNOPSIS. Trial identification and protocol summary
SYNOPSIS Trial identification and protocol summary Company: JANSSEN PHARMACEUTICA N.V. Finished product: Risperdal Active ingredient: Risperidone (R64766) Title: The safety and efficacy of risperidone
More informationComparison of the Usefulness of Lithium and Valproate
Review Article CNPT4(2013) 1-5 Comparison of the Usefulness of Lithium and Valproate, M.D., Ph.D. Department of Neuropsychiatry, Oita University Faculty of Medicine ABSTRACT This review shows that lithium
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationPharmacotherapy of Alcohol Use Disorders
Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationLithium toxicity. Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris
Lithium toxicity Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris Lithium Use of lithium salts as salt substitutes but recall from the marketplace in 1949 Efficient in the treatment
More informationPsychotropic Medication
Psychotropic Medication Part 3: Mood Stabilizers with Terry Broda MOOD STABILIZERS Carbolith, Duralith Depakene*, Epival*, Depakote* Lithium Valproic Acid, Divalproex Sodium Valproate Tegretol* Trileptal*
More informationAntidepressants. Professor Ian Jones May /WalesMentalHealth
Antidepressants Professor Ian Jones May 2017 www.ncmh.info @ncmh_wales /WalesMentalHealth 029 2074 4392 info@ncmh.info We identified 19 740 pregnancies exposed to an antidepressant at some point during
More informationTOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)
divalproex sodium TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) Pharmacodynamics study of what a drug does to the body Divalproex sodium is chemically compounded from sodium valproate and
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationDisclosures. Objectives. Talk Overview 11/28/2016. Advanced Perinatal Pharamcology
Advanced Perinatal Pharamcology Disclosures Legal consultant to Astra Zeneca, Eli Lilly, Johnson and Johnson Research Support from NIMH, Stanley Medical Research Foundation, SAGE Jennifer L. Payne, M.D.
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationAntidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych
Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych A. Heterocyclic antidepressants: (tricyclic and tetracyclic ), e.g.amitryptaline,imipramine. B. Monoamine oxidase inhibitors(m.a.o.i), e.g.phenelzine.
More informationGABAPENTIN. THERAPEUTICS Brands Neurontin see index for additional brand names
GABAPENTIN THERAPEUTICS Brands Neurontin see index for additional brand names Generic? Not in U.S. or Europe Class Anticonvulsant, antineuralgic for chronic pain, alpha 2 delta ligand at voltagesensitive
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationNeither activated charcoal nor whole bowel irrigation (WBI) is indicated in the routine management of acute or chronic lithium toxicity.
CRACKCast E160 Lithium Key concepts; The clinical pattern of acute and chronic toxicity is different. Gastrointestinal symptoms occur early and neurological toxicity manifest late in acute toxicity. Neurological
More informationBipolar Disorder Demystified. Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry
Bipolar Disorder Demystified Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry Underdiagnoses of Depression In Primary Care 2005 Study of 650 primary care patients on antidepressants
More informationZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide
Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide
More informationA case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY
A case of hypokalemia MIHO TAGAWA FIRST DEPARTMENT OF MEDICINE NARA MEDICAL UNIVERSITY Case 57 y.o. male CC: Weakness HPI: About 20 years ago, he developed bilateral lower extremity weakness. Laboratory
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN MIRTAZAPIN ORION 15MG, 30MG AND 45MG TABLETS ORION CORPORATION DATE: , VERSION 2
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN MIRTAZAPIN ORION 15MG, 30MG AND 45MG TABLETS ORION CORPORATION DATE: 16-12-2014, VERSION 2 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationPsychotropic Medications in Pregnancy. Leanne Martin MD, MSc (Medicine), FRCPC Psychiatrist Cambridge Memorial Hospital
Psychotropic Medications in Pregnancy Leanne Martin MD, MSc (Medicine), FRCPC Psychiatrist Cambridge Memorial Hospital Psychotropic Medications in Pregnancy Dr. Leanne Martin Day in Psychiatry 2018 Declaration
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationMaternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand
General Psychiatry Key Words: lamotrigine, mood stabilisers, bipolar disorder, fetal and maternal outcomes Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from
More informationSHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR LITHIUM 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of lithium.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in
More informationValproic acid. Brand Name: Depakene Drug Class: Opportunistic Infection and Other Drugs
Brand Name: Depakene Drug Class: Opportunistic Infection and Other Drugs Drug Description Valproic acid is a carboxylic acid that increases gamma-amino butyric acid (GABA) levels in the central nervous
More informationNursing Process Focus: Patients Receiving Chlorpromazine (Thorazine)
Nursing Process Focus: Patients Receiving Chlorpromazine (Thorazine) Potential Nursing Diagnoses Ineffective Therapeutic Regimen Management Risk for Activity Intolerance, related to side effect of drug
More informationAzathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS
Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least
More informationLinks to the following videos are also available online underneath the article abstract.
Supplementary Materials: Links to the following videos are also available online underneath the article abstract. 1. Supplementary Video 1: Itching due to kidney failure A patient s experience (vimeo.com/49458473)
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationApril 2016 Prepared By: Kimberly D. Griego, PharmD, CGP
April 2016 Prepared By: Kimberly D. Griego, PharmD, CGP Bipolar disorder (BD), also referred to as manic-depression, presents with dramatic swings in a person s mood and energy level, which affects their
More informationMental Health Medicines Management Pilot. Community Pharmacy Lithium Support Service Guidance
Mental Health Medicines Management Pilot Community Pharmacy Lithium Support Service Guidance Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact Aaron Coulter Group / Committee
More informationAppendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)
Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationDefinition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors:
INDICATION High grade lymphoma with high risk of CNS involvement Definition of high risk disease for diffuse large B-cell lymphoma is score 4 or 5 based on the following risk factors: Age > 60 Raised serum
More informationSummary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole)
EMA/370707/2016 Summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Mylan Pharma, which details the
More informationDepakote and ammonia level
Depakote and ammonia level The Borg System is 100 % Depakote and ammonia level Sermo: What is the standard of care for handling hyperammonemia with Depakote? Physicians Only. Routine ammonia level is unnecessary,
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationValproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationSupplementary Online Content
Supplementary Online Content Di Florio A, Forty L, Gordon-Smith K, Heron J, Jones L, Craddock N, Jones I. Perinatal episodes across the mood disorder spectrum. Arch Gen Psychiatry. Published online December
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationMonitoring of patients prescribed lithium
POMH-UK Topic 7 Monitoring of patients prescribed lithium Please use the following to cite this report: Prescribing Observatory for Mental Health (2009). Topic 7 baseline report. Monitoring of patients
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Schizophrenia Schizophrenia is a mental illness with a number of symptoms, including confused or unclear thinking and speech,
More informationRoles of primary care physicians in managing bipolar disorders in adults
CPG UPDATE Roles of primary care physicians in managing bipolar disorders in adults Awaluddin A, Jali N, Bahari R, Jamil Z, Haron N on behalf of Development Group Clinical Practice Guidelines Management
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationWHICH BIPOLAR MEDS TO USE IN PRIMARY CARE?
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences WHICH BIPOLAR MEDS TO USE IN PRIMARY CARE? JOHN KERN 8.16.18 GENERAL DISCLOSURES The University of Washington School
More informationOXCARBAZEPINE. THERAPEUTICS Brands Trileptal see index for additional brand names. Generic? Yes
OXCARBAZEPINE THERAPEUTICS Brands Trileptal see index for additional brand names Generic? Yes Class Anticonvulsant, voltage-sensitive sodium channel antagonist Commonly Prescribed for (bold for FDA approved)
More informationComposition: Each Tablet contains. Pharmacokinetic properties:
Composition: Each Tablet contains Torsemide 5/10/20/40/100mg Pharmacokinetic properties: Torsemide is well absorbed from the gastrointestinal tract. Peak serum concentrations are achieved within 1 hour
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More information( Thyrotoxicosis ) ( Hyperthyroidism ) ( Coma ) ( Hypercalcemia ) ( thyroid storm )
2007 18 201-205 ( thyroid storm ) ( 12.4 mg/dl ) ( intact parathyroid hormone ) 32 pg/ml ( 10-60 ) ( 140-150/min ) 36.9 ( 10.5 mg/dl ) ( BUN: 78 mg/dl, creatinine: 1.8 mg/dl ) TSH:
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationSupplementary Online Content
Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationPRODUCT INFORMATION QUILONUM SR
PRODUCT INFORMATION DESCRIPTION QUILONUM SR Quilonum SR contains lithium carbonate, a white, light alkaline powder with molecular formula Li 2 CO 3 and molecular weight 73.89. Quilonum SR tablets also
More informationThe most current assessment of this problem can be found in the Apex note dated
Him andpcos Smartphrase:.REFENDOPCOS NOTE: patients with suspected PCOS are welcomed to endocrine clinic. There is also a PCOS clinic is available in the Ob/Gyn Department. I am referring @name@, a @age@
More informationPrevention of Medication-Related Falls Through Appropriate Medication Use. Clay Sprouse, MEd., CPhT Piedmont Technical College
Prevention of Medication-Related Falls Through Appropriate Medication Use Clay Sprouse, MEd., CPhT Piedmont Technical College Disclosure I have no relevant financial or nonfinancial relationships to disclose
More informationLithium Intoxication with Sinus Node Dysfunction: Report of a Case
116 Lithium Intoxication with Sinus Node Dysfunction: Report of a Case Shu-Ping Chao 1, Huey-Ming Lo 1,2 Lithium has been reported to cause many cardiac side effects, such as T wave flattening, ST segment
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationCourse and Treatment of Depression and Bipolar Illness during Pregnancy : Knowns and Unknowns
Course and Treatment of Depression and Bipolar Illness during Pregnancy : Knowns and Unknowns Lee S. Cohen, MD Director, Ammon-Pinizzotto Center for Women s Mental Health Massachusetts General Hospital
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationAffective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018
Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed
More informationDisorders of water and sodium homeostasis. Prof A. Pomeranz 2017
Disorders of water and sodium homeostasis Prof A. Pomeranz 2017 Pediatric (Nephrology) Tool Box Disorders of water and sodium homeostasis Pediatric Nephrology Tool Box Hyponatremiaand and Hypernatremia
More informationSymbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)
Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination) Generic name: Olanzapine and fluoxetine combination Available strengths: 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg (Zyprexa/Prozac)
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationRiding the Waves: Tools for the Management of Bipolar Disorder
Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationLithium Shared Care Protocol and Information for Oxfordshire GPs
Summary Lithium Shared Care Protocol and Information for Oxfordshire GPs 1. Lithium is predominantly used in the following situations: a. The acute treatment of mania b. Prophylaxis in bipolar disorder
More information8-9 June Precision Medicine in Psychiatry. Pisa, Italy. From diagnostic stratification to treatment specificity
Precision Medicine in Psychiatry From diagnostic stratification to treatment specificity Medicina Personalizzata in Psichiatria Dalla stratificazione della diagnosi alla specificità della cura 8-9 June
More informationWEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationPRODUCT INFORMATION INSIG
PRODUCT INFORMATION INSIG NAME OF THE MEDICINE INSIG (Indapamide) DESCRIPTION Chemical name: Indapamide hemihydrate in 4-chloro-N(2-methyl-1-indolinyl)-3-sulfamoyl benzamide hemihydrate. Indapamide is
More informationSTUDY ON LITHIUM MONITORING AMONGST PATIENTS IN A COMMUNITY MENTAL HEALTH AND PRIMARY CARE SETTING IN RURAL ENGLAND
Medicinska naklada - Zagreb, Croatia Conference paper STUDY ON LITHIUM MONITORING AMONGST PATIENTS IN A COMMUNITY MENTAL HEALTH AND PRIMARY CARE SETTING IN RURAL ENGLAND Nicholas Savage 1, Jessica Green
More informationPediatric patients 2 years and older with partial onset seizures, primary generalized tonic-clonic LGS (2.1) Migraine (2.2) 400 mg once daily
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TOPIRAMATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for
More informationA systematic review of the evidence on the treatment of rapid cycling bipolar disorder
Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid
More informationJoseph S. Weiner, MD, PC Patient History Form
Date: / / NAME: Last First M. I. Age: Sex: q F q M Birthdate: / / What specific questions or goals do you have for this appointment? Please list the names of other clinicians you have seen for this problem:
More informationBipolar Disorders in Late Life. Robert C. Young, M.D. Department of Psychiatry Weill Medical College of Cornell University
Bipolar Disorders in Late Life Robert C. Young, M.D. Department of Psychiatry Weill Medical College of Cornell University 1 Self-Assessment Question 1 As reported by Himmelhoch et al in 1980, comorbid
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationElements for a Public Summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Schizophrenia Schizophrenia is a mental disorder often characterized by abnormal social behaviour and failure to recognize what
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationTransitions: Athanasios Koukopoulos [AθανσιΟ
Transitions: Athanasios Koukopoulos [AθανσιΟ κουκπουλο], M.D. (1931 2013) The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation
More information